Light seeing in patients with brain tumors and head and neck malignancies treated with radiotherapy
Keywords:
phosphene, Cherenkov radiation, radiotherapy, visual pathwayAbstract
Background:Reaching a better understanding of light vision in radiotherapy patients.
Materials and methods: 20 patients with brain tumors and head and neck malignancies who received radiotherapy and experienced any kind of light or color vision during radiation treatment. All the components of visual pathway were contoured.
Results: 11 patients were male and 9 were female (median age: 56 years). The range of dose/fraction and total prescribed dose were 1.8-3Gy and 36-70.4Gy respectively. Twelve patients reported white, 11, blue, 2, yellow and 2, gray color visions. Seven patients experienced more than one color, while 2 patients did not attribute any special color to their experiences. Four patients had a kind of smell experience and 1 patient had a taste experience.
Conclusion: Cherenkov radiation in eye balls may be the origin of light seeing experiences in patients receiving radiation treatment for head and neck malignancies, since treatmentsareperformed with ionizing radiations with energycapable to produce this effect. Also this effectmay be due to phosphenes produced by radiation treatment in different parts of the visual pathway (from retina to visual cortex). In order to investigate the mechanism of this phenomenon in patients and to define a radiation dose threshold – if the origin of this phenomenon is phosphenes produced in visual pathway – larger studies are needed.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.